Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

MacroGenics Highlights Preliminary Clinical Results From Single Arm Study Of Lorigerlimab

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved
byBenzinga Newsdesk
February 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90)
  • Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial responses
  • Manageable overall safety profile observed across multiple expansion cohorts
    • Company plans to initiate Phase 2 study in mCRPC in 2023M
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0